Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Tezepelumab: una nueva opción para el tratamiento del asma grave / Tezepelumab: a new option for the treatment of severe asthma
Resumen
Resumen
En Latinoamérica, el asma es un problema de salud pública con un impacto importante tanto para los pacientes como para los sistemas de salud. El mayor entendimiento de la fisiopatología y el reconocimiento del papel central que tiene la inflamación en la severidad del asma ha favorecido el desarrollo de anticuerpos monoclonales que tienen como blancos terapéuticos a la IL-5, IL-4, IL-13 y la IgE. Si bien estas alternativas terapéuticas favorecen un mejor control de la enfermedad, no todos los pacientes responden favorablemente a esos tratamientos. Por lo que resulta de particular interés explorar anticuerpos monoclonales como el Tezepelumab, dirigido contra la linfopoyetina estromal tímica (TSLP) una alarmina (citocina epitelial) que participa en el inicio y la perpetuación de la inflamación en el Asma. Por lo que, en esta revisión, mostraremos la eficacia clínica del tezepelumab en la disminución de la tasa anual de exacerbaciones, mejora en la función pulmonar y en la disminución en la hiperreactividad bronquial, independientemente de los niveles de biomarcadores basales que el paciente presente. Por lo que esta nueva molécula es una opción terapéutica altamente eficaz para el paciente con asma grave.
Abstract
In Latin America, asthma is a public health problem with a significant impact on both patients and health systems. The greater understanding of the pathophysiology and the recognition of the central role that inflammation has in the severity of asthma has favored the development of monoclonal antibodies that have IL-5, IL-4, IL-13 and IgE as therapeutic targets. Although these therapeutic alternatives promote better control of the disease, not all patients respond favorably to these treatments. Therefore, it is of particular interest to explore monoclonal antibodies such as Tezepelumab, directed against thymic stromal lymphopoietin (TSLP), an alarmin (epithelial cytokine) that participates in the initiation and perpetuation of inflammation in Asthma. Therefore, in this review, we will show the clinical efficacy of tezepelumab in reducing the annual rate of exacerbations, improving lung function, and reducing bronchial hyperreactivity, regardless of the patient’s baseline biomarker levels. Therefore, this new molecule is a highly effective therapeutic option for patients with severe asthma.
Palabras clave
Texto completo:
PDFReferencias
Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183-92.
The Global Asthma Report 2022. The Int J Tuberc Lung Dis. 2022;26:S1-102.
Forno E, Gogna M, Cepeda A, et al. Asthma in Latin America. Thorax. 2015;70(9):898.
Ocampo J, Gaviria R, Sánchez J. Prevalencia del asma en América Latina. Mirada crítica a partir del ISAAC y otros estudios. Revista Alergia México. 2017;64(2):188-97.
Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783-800.
Serrano CC, Moreno CM, Sánchez CA, et al. Normativa sobre asma grave no controlada. Arch de Bronconeumología. 2015; 51(5):235-46.
López-Tiro J, Contreras-Contreras A, Rodríguez-Arellano ME, et al. Economic burden of severe asthma treatment: A real-life study. World Allergy Organ J. 2022;15(7):100662.
Reibman J, Tan L, Ambrose C, et al. Clinical and economic burden of severe asthma among US patients treated with biologic therapies. Ann Allergy Asthma Immunol. 2021;127(3):318-325.
Yang D, Han Z, Oppenheim JJ. Alarmins and immunity. Immunol Rev. 2017;280(1):41-56.
Corren J, Ziegler SF. TSLP: from allergy to cancer. Nat Immunol. 2019;20(12):1603-9.
Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2023;23 (1):24-37.
Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Medicine. 2012;18(5):684-92.
Klose CSN, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol. 2016;17(7):765-74.
Colas L, Magnan A, Brouard S. Immunoglobulin E response in health and disease beyond allergic disorders. Allergy. 2022;77 (6):1700-18.
Pelaia C. Special Issue on ‘Asthma and Allergic Inflammation’. Nato Adv Sci Inst Se. 2023;11(3):531.
Redhu NS, Shan L, Movassagh H, et al. Thymic Stromal Lymphopoietin Induces Migration in Human Airway Smooth Muscle Cells. Sci Rep-uk. 2013;3(1):2301.
Kaur D, Doe C, Woodman L, et al. Mast Cell-Airway Smooth Muscle Crosstalk. The Role of Thymic Stromal Lymphopoietin. Chest. 2012;142(1):76-85.
Yamasaki A, Okazaki R, Harada T. Neutrophils and Asthma. Diagnostics. 2022;12(5):1175.
Li Y, Wang W, Lv Z, et al. Elevated Expression of IL-33 and TSLP in the Airways of Human Asthmatics In Vivo: A Potential Biomarker of Severe Refractory Disease. The J Immunol. 2018;200(7):2253-62.
Corren J, Parnes JR, Wang L, et al. Tezepelumab in Adults with Uncontrolled Asthma. New Engl J Med. 2017;377(10):936-46.
Schoettler N, Strek ME. Recent Advances in Severe Asthma: From Phenotypes to Personalized Medicine. Chest. 2020;157(3):516-528.
Parnes JR, Molfino NA, Colice G, et al. Targeting TSLP in Asthma. J Asthma Allergy. 2022;15:749-765.
Marone G, Spadaro G, Braile M, et al. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. Expert Opin Investig Drugs. 2019;28(11):931-940.
Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses. New England Journal of Medicine. 2014;370(22), 2102-2110.
Corren J, Garcia-Gil E, Griffiths JM, et al. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann Allergy Asthma Immunol. 2021;126(2):187-193.
Nordenmark L, Emson C, Hellqvist Å, et al. S46 Tezepelumab reduces mucus plugging in patients with uncontrolled, moderate-to-severe asthma: the phase 2 CASCADE study. Thorax. 2022;77:A32.
Menzies-Gow A, Colice G, Griffiths JM, et al. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020;21(1):266.
Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Respir Medicine. 2021;9(11):1299-312.
Alpizar S, Megally A, Chen C, et al. Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma. J Asthma Allergy. 2021;14:381-92.
Wechsler ME, Colice G, Griffiths JM, et al. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 2020;21(1):264.
Menzies-Gow A, Wechsler ME, Brightling CE, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo controlled extension study. Lancet Respir Med. 2023;11(5): 425-438.
Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757-65.
M. Castro (Kansas City, United States), C. Ambrose (Gaithersburg, United States), G. Colice (Gaithersburg, United States), et al. On-treatment clinical remission with tezepelumab among patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study. International Congress 2022 - Recent advances in biological treatments for asthma.
Roy P, Rafa Z, Haque S, et al. The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Ran domized Controlled Trials. Cureus. 2022;14(12):e32156.
Emson C, Corren J, Sałapa K, et al. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study. J Asthma Allergy. 2021;14:91-9.
DOI: https://doi.org/10.24875/10.5281/zenodo.10064422
Enlaces refback
- No hay ningún enlace refback.